Thirty-three studies were excluded from further review because they included only lung cancer patients, two were excluded because they were diagnostic/non-interventional studies, and one each was excluded for not being specific to G12C-mutant tumors or having KRAS mutations as an exclusion criterion. This evidence concerns the gene KRAS and lung carcinoma.